Brief: 60 Degrees Pharmaceuticals Suspends Phase Iib Study Of Tafenoquine For Covid-19
12/10/2023 21:53
Oct 12 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMACEUTICALS SUSPENDS PHASE IIB STUDY OF
TAFENOQUINE FOR COVID-19, PIVOTS TO REFOCUS ON COMMERCIALIZATION
OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES
* 60 DEGREES PHARMACEUTICALS INC - COMPANY IS PREPARING FOR
SUBMISSION OF A PRE-IND MEETING REQUEST WITH FDA FOR BABESIOSIS
IN CURRENT Q4 OF 2023
* 60 DEGREES PHARMACEUTICALS INC- PLANS TO APPOINT A CHIEF
COMMERCIAL OFFICER TO LEAD ARAKODA COMMERCIALIZATION
Source text for Eikon: ID:nGNXcghTq5
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM